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Abstract. PEX5 encodes the type-1 peroxisomal tar- 
geting signal (PTS1) receptor, one of at least 15 perox- 
ins required for peroxisome biogenesis. Pex5p has a bi- 
modal distribution within the cell, mostly cytosolic with 
a small amount bound to peroxisomes. This distribution 
indicates that Pex5p may function as a cycling receptor, 
a mode of action likely to require interaction with addi- 
tional peroxins. Loss of peroxins required for protein 
translocation into the peroxisome (PEX2 or PEX12) 
resulted in accumulation of Pex5p at docking sites on 
the peroxisome surface. Pex5p also accumulated on 
peroxisomes in normal cells under conditions which in- 
hibit protein translocation into peroxisomes (low tem- 
perature or ATP depletion), returned to the cytoplasm 
when translocation was restored, and reaccumulated on 
peroxisomes when translocation was again inhibited. 
Translocation inhibiting conditions did not result in 
Pex5p redistribution in cells that lack detectable perox- 
isomes. Thus, it appears that Pex5p can cycle repeat- 
edly between the cytoplasm and peroxisome. Altered 
activity of the peroxin defective in CG7 cells leads to 
accumulation of Pex5p within the peroxisome, indicat- 
ing that Pex5p may actually enter the peroxisome lu- 
men at one point in its cycle. In addition, we found that 
the PTS1 receptor was extremely unstable in the per- 
oxin-deficient CG1, CG4, and CG8 cells. Altered distri- 
bution or stability of the PTS1 receptor in all cells with 
a defect in PTS1 protein import implies that the genes 
mutated in these cell lines encode proteins with a direct 
role in peroxisomal protein import. 
p 
ROXISOMAL proteins are encoded by nuclear genes, 
synthesized in  the  cytoplasm, and  imported  into 
peroxisomes posttranslationally. Therefore, the cel- 
lular mechanisms which mediate import of newly synthe- 
sized peroxisomal proteins must be able to recognize these 
proteins, transport them from the cytoplasm to the peroxi- 
some, and then catalyze their translocation across the per- 
oxisome membrane. Recognition of peroxisomal  proteins 
is dependent upon the presence of peroxisomal targeting 
signals  (PTSs) 1 within these proteins.  Most peroxisomal 
matrix proteins contain the PTS1, a tripeptide consisting 
of  serine-lysine-leucinecoori,  or  a  conservative  variant 
(Gould et al., 1989; de Hoop and AB, 1992). In contrast to 
the PTS1, the PTS2 is located at the NH2 terminus of pro- 
teins and mediates import of far fewer proteins (Osumi 
et al., 1991; Swinkels et al., 1991; Subramani, 1993). Like 
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the PTS1, the PTS2 also appears to fit a loose consensus 
sequence, R/KQ/HxsQ/HL, and  also  directs  proteins  to 
the  peroxisome lumen. Evidence for internal PTSs  has 
also been reported (Kragler et al., 1993; Small et al., 1988), 
but the critical features of these signals are yet to be de- 
fined. Interestingly, proteins can enter the peroxisome lu- 
men even if they lack a PTS, provided that they oligomer- 
ize with a PTS-containing  protein before import (Glover 
et al., 1994; McNew and Goodman, 1994). Thus, it is possi- 
ble  that  homo- or  hetero-oligomerization domains may 
function as targeting signals even though they do not me- 
diate direct interaction with a PTS receptor. Another sur- 
prising aspect  of peroxisomal protein import is that inte- 
gral  peroxisomal  membrane  proteins  (IPMPs)  do  not 
simply use a matrix targeting signal in combination with a 
hydrophobic  membrane-spanning  segment  (Subramani, 
1993). Instead, they appear to contain a completely dis- 
tinct type of targeting signal (Dyer et al., 1996) and an in- 
sertion element which remains to be identified. 
Many  recent  advances  in  understanding peroxisome 
biogenesis have come from the analysis of mutant cells de- 
fective in peroxisomal protein import. Human cells with 
this phenotype have been obtained from patients afflicted 
with  the  peroxisome  biogenesis  disorders  (PBD)  (Laz- 
arow and Moser,  1995; Moser et al., 1995; Motley et ai., 
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1992).  The PBD are a group of lethal genetic diseases in- 
cluding  Zellweger  syndrome,  neonatal  adrenoleukodys- 
trophy, infantile Refsum disease, and rhizomelic chondro- 
dysplasia punctata. Of these, Zellweger syndrome, neonatal 
adrenoleukodystrophy, and infantile Refsum disease rep- 
resent gradations of the same phenotypes (Zellweger syn- 
drome being the most severe), while rhizomelic chondrod- 
ysplasia punctata is characterized by a very different set of 
characteristics. Although these diseases span a wide range 
of clinical  phenotypes,  all  are  characterized  by  severe 
mental retardation and appear to be the result of specific 
defects in peroxisome biogenesis. Somatic cell fusion stud- 
ies using skin fibroblasts from PBD patients indicate that 
defects in any of at least ten genes can cause these disor- 
ders (Moser et al., 1995; Shimozawa et al., 1993). The anal- 
ysis of the protein import capacities of PBD cell lines from 
groups 1-4  and 7-11  (Slawecki et al.,  1995) has revealed 
that defects in all but the CGll gene can result in defects 
in  both  PTS1  and  PTS2  protein  import.  Furthermore, 
while PBD cell lines representing CGs 1, 4, and 8 retain 
the ability to import at least some PTS1 and PTS2 proteins 
into  peroxisomes,  some  CG3  and  CG10  cells  exhibit  a 
complete defect in matrix protein import (Slawecki et al., 
1995).  CG2 patients have been shown to carry mutations 
in PEX5, the PTS1 receptor gene, and exhibit either a spe- 
cific defect in PTS1 protein import or an inability to import 
PTS1 and PTS2 proteins (Dodt et al., 1995; Wiemer et al., 
1995).  Not surprisingly, the selective PTS2 protein import 
defect of CGll cells (Motley et al., 1994; Slawecki et al., 
1995)  is caused by mutations in the PTS2 receptor gene, 
PEX7 (Braverman, N., G. Dodt, S.J. Gould, and D. Valle, 
manuscript  submitted  for  publication).  CG9  cells  are 
unique in that they lack detectable peroxisomes and are 
likely to  be  defective in  either synthesis  of peroxisome 
membranes  or  targeting  of  integral  peroxisomal  mem- 
brane  proteins  (Chang  C.-C.,  G.  Dodt,  and  S.J.  Gould, 
manuscript in preparation). Other known PBD genes in- 
clude  PEX2,  PEX6,  and  PEX12,  the  genes defective in 
complementation groups  10,  4,  and  3,  respectively (Shi- 
mozawa et al., 1992; Yahraus et al., 1996; Chang, C.-C., D. 
Valle, and S. J. Gould, manuscript in preparation). 
Yeast strains unable to import the normal complement 
of peroxisomal  proteins  have  also  been  isolated.  These 
peroxisome assembly (pex) mutants have been isolated us- 
ing a  variety of genetic screens and selections in several 
different organisms: Saccharornyces  cerevisiae, Pichia pas- 
toris,  Hansenula  polymorpha,  and  Yarrowia  lipolytica 
(Cregg et al.,  1990; Elgersma et al.,  1993; Erdmann et al., 
1989;  Gould et al.,  1992;  Liu et al.,  1992;  Nuttley et al., 
1993; Kalish et al., 1996). To date, fifteen distinct comple- 
mentation groups of yeast pex mutants have been reported 
(Elgersma et al.,  1993) and 13 PEX proteins, or peroxins, 
have been characterized (Distel et al.,  1996). As with hu- 
man PBD cells, yeastpex mutants appear to fall within five 
general categories: (1) those with a complete defect in pro- 
tein translocation (Kalish et al.,  1995), (2) those with re- 
duced import efficiency (Heyman et al., 1994; Spong and 
Subramani,  1993),  (3)  a  single  complementation  group 
that exhibits a PTSl-specific import defect (McCollum et al., 
1993; van der Klei et al.,  1993,  1995), (4) another with a 
PTS2-specific import defect (Marzioch et al., 1994; Zhang 
and Lazarow, 1995), and (5) one with a defect in peroxi- 
some synthesis and/or targeting of IPMPs (Waterham et al., 
1993; Baerends et al., 1996; Wiemer et al., 1996). 
The  PTSl-specific import  defect  in  both  human  and 
yeast cells is caused by mutations in PEX5, the PTS1 re- 
ceptor gene. The human and yeast forms of the PTS1 re- 
ceptor are closely related tetratricopeptide repeat (TPR) 
proteins with intrinsic PTSl-binding activity mediated via 
their  TPR  domains  (Dodt  et  al.,  1995;  Terlecky et  al., 
1995).  However, the yeast and human forms of Pex5p dif- 
fer because the loss of the yeast PTS1 receptor has no ef- 
fect on the import of PT2 proteins (McCollum et at., 1993; 
van der Leij et al., 1993), while the human PTS1 receptor 
is  required for PTS2 protein  import  (Dodt  et al.,  1995; 
Slawecki et al.,  1995; Wiemer et al., 1995; Braverman, N., 
G. Dodt, S.J.  Gould, and D. Valle, manuscript submitted 
for publication). 
Because the PTS1 receptor plays such a central role in 
the protein import process, knowing its subcellular distri- 
bution  would  help  distinguish  between  several  possible 
models for peroxisomal protein import. Although early re- 
ports on the distribution of the PTS1 receptor from the 
yeast P. pastoris (PpPex5p)  indicated  it was  an  integral 
peroxisomal membrane  protein  (McCollum  et  al.,  1993; 
Terlecky et al.,  1995), we have found that PpPex5p is  a 
predominantly cytoplasmic protein: only 5% or less is per- 
oxisome associated  at  steady state  (Gould et  al.,  1996). 
This distribution closely mirrors that reported for the hu- 
man PTS1 receptor (Dodt et al.,  1995), as well as that of 
Pex5p from the yeast S. cerevisiae (Elgersma et al., 1996). 
The bimodal distribution of Pex5p indicates that the re- 
ceptor may cycle between these two compartments as it 
mediates transport of newly synthesized PTS1 proteins to 
and  into the  peroxisome. The recent identification of a 
docking factor for the PTS1  receptor in  the peroxisome 
membrane lends further support to this notion (Gould et al., 
1996; Elgersma et al.,  1996; Erdmann and Blobel, 1996). 
However, there is no other evidence for the cycling recep- 
tor model. Elucidation of many biochemical processes has 
relied on the characterization of precursors which accumu- 
late in cells blocked in different steps of a given pathway. 
We applied this principle of precursor accumulation to the 
analysis of PTS1 receptor function by examining the distri- 
bution and stability of Pex5p in cells lacking other defined 
and undefined peroxins blocked at different steps in per- 
oxisomal protein import. Our data indicate that Pex5p is a 
mobile receptor capable of cycling repeatedly between the 
cytoplasm  and  peroxisome.  Furthermore,  we  observed 
that multiple peroxins are required for Pex5p stability and 
that all peroxins required for normal PTS1 protein import 
affect PTS1 receptor distribution or stability. 
Materials and Methods 
Cell Lines, Antibodies, and Immunofluorescence 
Skin fibroblasts from PBD patients are referred to by their PBD number 
and were cultured as described (Slawecki et al., 1995). Rabbit polyclonal 
antibodies generated against Pex5p have been described previously (Dodt 
et al., 1995). The polyclonal anti-PMP70 antibodies were provided by S. 
Subramani, UC San Diego, La Jolla, CA. Monoclonal anti-myc antibodies 
(1-9E10;  BABCO, Berkeley, CA), sheep anti-catalase (The Binding Site, 
Birmingham, UK), and fluorescent-labeled secondary antibodies (Kirke- 
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commercial sources. Transfection experiments and indirect immunofluo- 
rescence microscopy were l~edormed according to established methods 
(Stawecki et al, 1995).  Unless otherwise noted, cells were permeabilized 
with 1% Triton X-100 for 5 min. For differential permeabilization experi- 
ments in which only the plasma membrane is disrupted, cells were incu- 
bated in buffered 25 i~g/ml digitonin for 5 min instead of 1% Triton X-100 
(Swinkels et al., 1991). All differential permeabilization experiments were 
performed side by side with appropriate controls to ensure that the digito- 
nin treatment did not permeabilize the peroxisome membrane. 
A TP Depletion Experiments 
Fibroblasts were incubated in either serum-free normal medium DMEM 
or ATP depletion medium (DMEM lacking glucose, supplemented with 
50 mM 2-deoxy p-glucose and 5 mM sodium azide) for specified periods 
of time. When ATP depletion was combined with low temperature incu- 
bation, the cells were first incubated in ATP depletion medium for 15 min 
at 37°C, and then shifted to 16°C for the indicated period of time. 
Metabolic Labeling and lmmunoprecipitations 
Fibrobtasts were grown on 60-ram dishes to 70% eonfluency in DMEM 
supplemented with 10% FCS (DMEM/10% FCS). The cells were washed 
twice with DMEM/5%  FCS without methionine and cysteine and incu- 
bated in this medium for 30 rain. Cells were pulsed for 1 h  with 1 mCi 
[35S]methionine/[35S]cysteine in 1 ml medium. The cells were washed two 
times with HBSS and chased in DMEM/10%FCS with 10 mM methionine 
and cysteine for the times indicated and under the stated conditions. After 
two washes with HBSS the ceils were incubated for 15 min on ice in 0.5 ml 
cold lysis buffer (50 mM Tris, pH 7.5,  150 mM NaCI, 5 mM EDTA, 1% 
Triton X-100, 0.2% SDS, 0.1 mM PMSF, and 1 p.g/ml aprofinin, and 1 p.g/ml 
leupeptin). Cell lysates were scraped from the plate with an additional 200 Izl 
buffer, agitated vigorously, and cleared by eentrifugation at 12,000 g for 15 
min at 4°C. The resulting supernatant was incubated with 20 tzl of a  1:1 
slurry of protein  A  beads (Pharmacia LKB Biotechnology, Piscataway, 
N J) for 1 h, the beads were removed by centrifugation, and the resulting 
supernatant was incubated with 2 ml of either preimmune or immune anti- 
Pex5p serum for 2 h at 4°C. 20 i~1 of protein A  beads were added, incu- 
bated for an additional hour, and collected by centrifugation. The beads 
were washed and the proteins recovered in 40 ~1 SDS sample buffer. Sam- 
ples were boiled for 5 rain, resolved by SDS-PAGE, and labeled proteins 
were detected by fluorography. 
Protein Extracts and lmmunoblotting 
For determining levels of Pex5p in the cell, fibroblasts were grown to 90% 
confluency in 60-ram dishes, washed two times with HBSS, removed from 
the plate, and recovered by centrifugation at 500 g for 10 rain. After two 
additional washes, the cells were resuspended in 50 txl water. An aliquot 
was removed for protein  determination and the samples were immedi- 
ately boiled in SDS sample buffer and frozen. For cell fractionations, cells 
were lysed as described (Dodt et al., 1995) and organelles were separated 
from cytosot by centrifugation at 14,000 g. Immunoblot analysis of the su- 
pernatant and pellet fractions using anti-PMP70 antibodies confirmed that 
the 14,000-g spin was sufficient to pellet all of the peroxisome membranes 
in the cell. The quantity of Pex5p in each supernatant and pellet sample 
was determined by SDS-PAGE and immunoblot using anti-Pex5p anti- 
bodies (Dodt et al., 1995). 
Results 
Pex5p Accumulates on Peroxisomes  Under 
Translocation  Inhibiting Conditions 
The observation that  the  PTS1  receptor in both human 
and  yeast  cells  is  a  predominantly  cytoplasmic protein 
(Dodt et al., 1995; Gould et al., 1996) indicated that Pex5p 
may function as a cycling receptor, guiding newly synthe- 
sized peroxisomal proteins from the cytoplasm to the per- 
oxisome and then returning to the cytoplasm to repeat the 
process. Since a cycling receptor would have to migrate to 
and bind the peroxisome before the protein translocation 
Table L The Peroxisomal Protein Import Defects of  PBD Cell 
Lines Representing  Nine Complementation  Groups 
Complete  Partial 
PTSI andPTS2  PTSI andPTS2 
Complementalion  PTSl-specific  PTS2-specific  protein import  protein import 
group  import defect  import defect  defect  defect 
CG1  0  0  0  10 of I0 
CG2  2 of 3  0  1 of 3  0 
CG3  0  0  4 of 4  0 
CG4  0  0  0  20 of 20 
CG7  0  0  0  3 of 3 
CG8  0  0  0  8 of 8 
CG9  0  0  1 of 1  0 
CG10  0  0  2 of 2  0 
CG11  0  13 of 13  0  0 
event, inhibiting translocation would lead to Pex5p accu- 
mulation at the prior step in import, i.e., docking to the 
peroxisome membrane. The extent of accumulation would 
depend  on the relative abundance of the PTS1 receptor 
and Pexl3p, the IPMP which functions as a docking factor 
for the receptor (Gould et al., 1996; Elgersma et al., 1996; 
Erdmann and Blobel, 1996), as well as the degree of trans- 
location inhibition. 
The cycling receptor hypothesis was first tested by com- 
paring the distribution of Pex5p in control fibroblasts and 
fibroblasts that are unable to import matrix proteins into 
the peroxisome lumen. As previously reported (Dodt et al., 
1995), the amount of peroxisome associated Pex5p in nor- 
mal human fibroblasts is so low that only the cytoplasmic 
form is detected using our standard indirect immunofluo- 
rescence protocol (Fig. 1 A). In contrast, peroxisome asso- 
ciated Pex5p was readily detected in fibroblasts from both 
CG3 (Fig. 1 B) and CG10 (Fig. t  C) PBD patients, cells 
which are unable to translocate peroxisomal matrix proteins 
into the peroxisome (Table I; Slawecki et al., 1995). The 
colocalization of Pex5p  and  the  peroxisomal membrane 
marker PMP70myc in these cells (Fig. 1 D) confirmed that 
the Pex5p-containing vesicles were indeed peroxisomes (not 
all peroxisomes contained both Pex5p and PMP70myc but 
heterogeneity of peroxisomal content has been noted pre- 
viously; Luers et al., 1993). To test whether Pex5p had ac- 
cumulated  on  the  outer  surface  of peroxisomes or  had 
been  imported into these vesicles, CG3  and CG10 cells 
were subjected to differential permeabilization immuno- 
fluorescence experiments  in  which  only cytoplasmically 
exposed antigens are detected (Swinkels et al., 1991). Per- 
oxisomal Pex5p was still detected under these conditions, 
indicating  that it had accumulated on or near the outer 
surface of the peroxisome in CG3 and CG10 cells (Fig. 1, 
E and F). 
The  subcellular  distribution  of Pex5p  in  normal  and 
CG10 fibroblasts was  also examined by differential cen- 
trifugation. Cell free lysates were prepared from N1 (unaf- 
fected control) and CG10 fibroblasts and separated  into 
supernatant  and organelle fractions by centrifugation at 
14,000 g (it was not possible to further purify peroxisomes 
from these cells because they migrate at an anomalously 
low density due to their lack of matrix content). Each sam- 
ple was then subjected to immunoblot analysis using anti- 
bodies specific for Pex5p (Fig. 2). As demonstrated previ- 
ously (Dodt et al.,  1995),  only a  small  amount  (5%)  of 
Dodt and Gould A Cycling Receptor  for PTS1 Proteins  1765 Figure 1.  Pex5p accumulates on the peroxisome surface in PBD cells defective in peroxisomal protein translocation. Indirect immuno- 
fluorescence  microscopy using antibodies  specific for Pex5p in (A) normal human fibroblasts  and (B) CG3 fibroblasts  (PBD006). The 
CG10 cell line PBD094 was transfected with a vector designed to express PMP70myc, allowing detection of peroxisome membranes, 
and subsequently  processed for indirect immunofiuorescence  using antibodies  specific for (C) Pex5p and (D) the myc epitope tag at the 
COOH-terminus of PMP70myc. (E) CG3 (PBD095) and (F) CG10 (PBD062) cells were also processed for differential  (digitonin) per- 
meabilization indirect immunofluorescence  using anti-Pex5p antibodies. Bar, 25 ~m. 
Pex5p was organelle associated in wild-type cells. In con- 
trast,  25%  of  Pex5p  was  organelle  associated  in  CG10 
ceils,  confirming  that  the  translocation  block correlated 
with a  redistribution of Pex5p from the cytoplasm to the 
peroxisome.  It  is  important  to  note  that  a  significant 
amount of Pex5p is cytosolic even in CG10 cells. This is 
not surprising considering that Pex13p, the docking factor 
for the  PTS1  receptor, is  a  low  abundance  peroxisomal 
membrane protein (our unpublished observations)~ ~100- 
fold  less  abundant  than  PMP27,  another  peroxisomal 
membrane  protein  (Erdmanrt,  R.,  personal  communica- 
tion). Serial analysis of gene expression (Velculescu et al., 
1995)  in human cells revealed that PEX5 mRNA may be 
fourfold  more  abundant  than  PEX13  mRNA  in  human 
cells (data not shown).  If the levels of Pex5p and Pexl3p 
reflect the abundance of their mRNAs, 25% would be the 
most Pex5p that could accumulate on peroxisomes. 
We next examined whether the PTS1 receptor could be 
trapped  on  the  peroxisome in  normal human fibroblasts 
by incubating the cells at low temperature or under ATP 
depleting conditions.  Previous studies have demonstrated 
that protein translocalion into the peroxisome is inhibited 
by low temperature or by depleting ATP levels (Imanaka 
et  al.,  1987;  Miyazawa et  al.,  1989;  Walton  et  al,  1992; 
Wendland and Subramani, 1993).  Pex5p is predominantly 
cytoplasmic in normal human fibroblasts (Fig. 3 A) but ac- 
cumulated on peroxisomes after a 2-h incubation  at 16°C 
in  ATP  depletion  medium  (lacking  glucose  and  supple- 
mented with 2-deoxyglucose and sodium azide) (Fig. 3 B). 
Differential  permeabilization  and  colocalization  experi- 
The Journal of Cetl Biology, Votume 135,  1996  1766 Figure  2.  Levels  of peroxisome  associated  Pex5p  are  elevated 
fivefold in PEX2-deficient cells. The CG10 cell line PBD094 and 
the control cell line N1 (Slawecki  et al., 1995) were gently lysed 
and  separated  into organellar  pellet  and  cytosolic supernatant 
fractions by centrifugation. The supernatant and pellet fractions 
from each cell line were separated by SDS-PAGE and processed 
for immunoblot with anti-Pex5p antibodies.  Lane 1, control su- 
pernatant; lane 2, control pellet; lane 3, CG10 supernatant; lane 4, 
CG10 pellet.  The slower migrating band represents  a modified 
form of Pex5p. The precise nature of the modification remains to 
be determined.  Immunoblot analysis  of the same samples with 
anti-PMP70 antibodies revealed that the 14,000-g spin was suffi- 
cient to quantitatively pellet peroxisomes from the lysates. 
ments confirmed that Pex5p was present on the outer surface 
of the peroxisome under these conditions (data not shown). 
The distribution of Pex5p in these experiments was also 
examined by differential centrifugation. Normal human fi- 
broblasts  incubated  in growth medium  or in ATP deple- 
tion medium for 1 h were gently lysed and the resulting ex- 
tract was separated into a supernatant of cytosolic proteins 
and an organelle pellet. Immunoblot analysis of these frac- 
tions  using  anti-Pex5p  antibodies  (Fig.  4)  revealed  that 
14%  of Pex5p was organelle  (peroxisome)  associated un- 
der translocation inhibiting conditions. This is a significant 
increase relative to the 5%  observed in cells grown under 
normal conditions but somewhat less than the 25%  accu- 
mulation observed in CG10 cells (refer to Fig. 2). Possible 
reasons for the lower accumulation of peroxisome associ- 
ated Pex5p in this experiment are that (1) ATP depletion 
may only inhibit translocation, not abolish the process, (2) 
the technique used to deplete ATP is unlikely to eliminate 
all ATP in the cell, and (3) the duration of the transloca- 
tion inhibition in these experiments  was only 1 h, as com- 
pared to constitutive inhibition in the translocation defec- 
tive CG10 cells. 
Figure 4.  Levels of peroxisome associated Pex5p in normal cells 
increase  under translocation  inhibiting  conditions.  The control 
cell line N1 was grown under normal conditions or in ATP deple- 
tion medium for I h and subsequently lysed. Each lysate was sep- 
arated into organellar pellet and cytosolic supernatant fractions 
by centrifugation. The supernatant and pellet fractions from both 
samples were separated by SDS-PAGE and processed for immu- 
noblot with  anti-Pex5p antibodies. Lane 1, control supernatant; 
lane 2, control pellet; lane 3, -ATP supernatant; lane 4, -ATP 
pellet. 
Pex5p Is a  Cycling Receptor 
If the migration of cytoplasmic Pex5p to the peroxisome 
represented  the first half of a  normal transport circuit for 
Pex5p,  then  releasing  the  translocation  inhibition  should 
allow the receptor to continue its circuit and return to the 
cytoplasm.  This  hypothesis  was  tested  in  normal  cells  in 
which  translocation  was  inhibited  by  low  temperature 
alone. Pex5p accumulated on peroxisomes after a 2-h incu- 
bation at 16°C (Fig. 5, A  and B) but returned  to the cyto- 
plasm after the cells were shifted back to 37°C for I  h (Fig. 
5  C). When the inhibited  and recovered cells (2 h  at 16°C 
followed by 1 h  at 37°C) were shifted back to 16°C for an 
additional  2  h, Pex5p again accumulated  on peroxisomes 
(Fig. 5 D), indicating that the receptor was capable of re- 
peatedly cycling between the cytoplasm and peroxisome. 
Although these results were consistent with a  model in 
which  the  PTS1  receptor  cycles  between  the  cytoplasm 
and peroxisome,  these  data were  also consistent  with  se- 
lective  degradation  of the  cytoplasmic form of the  PTS1 
receptor  at  16°C,  with  rapid  resynthesis  at  37°C.  To  ad- 
dress this possibility, normal human fibroblasts were pulse 
labeled with a mixture of [35S]methionine and [35S]cysteine 
for 1 h  at 37°C. After the pulse, cells were lysed immedi- 
ately (t -- 0), chased for 5 h  at 37°C (5 h  37°C), or chased 
for 2 h  at 16°C, 1 h  at 37°C, and 2 h  at 16°C (5 h TS (tem- 
perature  shift)).  At each  time  point  the  cells  were  lysed 
Figure 3.  Conditions which inhibit protein translocation across the peroxisome membrane lead to accumulation of Pex5p on peroxi- 
somes. The distribution of Pex5p in normal skin fibroblasts incubated at (A) 37°C in normal growth medium or (B) for 1 h at 16°C in 
ATP depletion medium was determined by indirect immunofluorescence microscopy. Bar, 25 txm. 
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lysate. Quantitation of Pex5p levels in each sample (Fig. 
5  E)  revealed  that  the  temperature  shift  conditions  re- 
suited  in  slight stabilization  of the  PTS1  receptor. Thus, 
there  was  no  evidence  for  selective  loss  of cytoplasmic 
Pex5p by incubation  at  16°C.  Furthermore, over the 5  h 
course of the experiment almost 70% of Pex5p present at 
t =  0 was present at t =  5 h, indicating that we were prima- 
rily observing the same population of PTS1 receptor mole- 
cules throughout the experiment. Similar changes in Pex5p 
distribution were observed when this experiment was re- 
peated in the presence of cycloheximide (data not shown). 
We also tested whether Pex5p would cycle back to the 
cytoplasm in CG10 cells after correction of their transloca- 
tion  defect.  CG10 cells are  homozygous for inactivating 
mutations in the PEX2 gene and transfection of the PEX2 
cDNA into  CG10 cells restores peroxisomal protein im- 
port  (Shimozawa et al.,  1992).  We transfected the  CG10 
cell line PBD094 with a plasmid which expresses the wild- 
type PEX2 gene. Only cytoplasmic Pex5p was detected in 
CG10  cells  expressing  PEX2  while  noncomplemented 
CG10 cells retained the  peroxisomal staining pattern for 
Pex5p (data not shown). 
Pex5p Cannot be Trapped on or in Peroxisomes in Cells 
Which Lack Peroxisome Membranes 
We  recently  completed  an  analysis  of  IPMP  import  in 
PBD  cell  lines  (Chang,  C.-C.,  G.  Dodt,  and  S.J.  Gould, 
manuscript  in  preparation)  to  complement  our  earlier 
analysis of matrix protein import in these cells (Slawecki 
et al., 1995).  As expected from the seminal observations of 
Santos et al. (1988), IPMP targeting was intact in the vast 
majority of PBD  cells,  including  representatives of com- 
plementation groups 1, 2, 3, 4, 7, 8, 10, and 11.  However, 
peroxisomes could not be detected in  PBD061  cells (the 
sole representative of PBD  group 9),  indicating  that the 
CG9 gene  is  required  for synthesis of peroxisome mem- 
branes  or  targeting  IPMPs  into  the  peroxisome  mem- 
brane. The absence of detectable peroxisome membranes 
in PBD061 cells makes them an excellent cell line in which 
to test the specificity of Pex5p accumulation under translo- 
cation inhibiting conditions.  Only cytoplasmic Pex5p was 
detected in PBD061 cells under normal growth conditions 
(Fig. 6 A) or after incubation in ATP depleting medium at 
16°C for 1 h (Fig. 6 B), conditions which lead to significant 
peroxisomal accumulation of Pex5p in control cells. 
The I~S1 Receptor Is Translocated into Peroxisomes in 
CG7 Cells 
In contrast to CG3, CG10, and CG9 cells, all three CG7 
cell lines import detectable levels of both PTS1 and PTS2 
Figure 5.  Peroxisomal accumulation  of Pex5p in response to low 
temperature incubation  is reversible.  Normal human fibroblasts 
were processed for indirect  immunofluorescence  after (A) incu- 
bation at 37°C, (B) a 2-h incubation  at 16°C, (C) a 2-h incubation 
at 16°C followed by a 1-h incubation  at 37°C, and (D) incubation 
for 2 h at 16°C, 1 h at 37°C, followed by an additional  2 h at 16°C. 
(E) Pulse-chase  analysis of Pex5p  during  the temperature shift 
experiment.  Cells were pulse  labeled with  [35S]methionine and 
[35S]cysteine, washed, and either lysed immediately or chased for 
5 h under the identical temperature shift conditions as in D above 
(5 h TS) or for 5 h at 37°C (5 h 37°C). Pex5p was immunoprecipi- 
tated from the lysates at the given time points. 70% of Pex5p syn- 
thesized at the beginning of the experiment was still present at its 
conclusion whereas slightly less (65%) was present in cells incu- 
bated at 37°C for the same length of time. Bar, (D) 25 pxm. 
The Journal of Celt Biology,  Volume 135, 1996  1768 Figure 6.  Pex5p cannot be trapped on peroxisomes in cells which lack detectable peroxisomes. The sole CG9 cell line exhibits a defect in 
synthesis of peroxisome membranes. The distribution  of Pex5p was determined by indirect immunofluorescence  in PBD061 (CG9) cells 
(A) incubated at 37°C in normal growth medium and (B) incubated for I h at 16°C in ATP depletion  medium. Bar, 25 ~m. 
proteins into peroxisomes. In fact, the  amount of matrix 
protein import in these cell lines was considerably higher 
than in any other PBD cell lines we have examined (Table 1; 
Slawecki et al., 1995).  Based on their high degree of matrix 
protein  import, we  expected that  the  distribution  of the 
PTS1 receptor in CG7 cells would resemble that of wild- 
type cells. Surprisingly, Pex5p was peroxisome associated 
in  the  CG7  cell  lines  PBD054  (Fig.  7  B),  PBD052,  and 
PBD053. Even more surprising was the fact that vesicular 
Pex5p could not be detected in differential permeabiliza- 
tion immunofluorescence experiments (Fig. 7  C), indicat- 
ing that Pex5p is translocated into the peroxisome lumen 
in these CG7 cells. 
The Stability of the PTS1 Receptor Is Severely Reduced 
in CG1, CG4, and CG8 Cells 
Immunofluorescence  analysis  failed  to  detect  Pex5p  in 
CG1 cells. To determine whether levels of Pex5p were re- 
duced  in  these  cells,  total cell protein was isolated from 
control and  PBD  cells and  Pex5p  abundance  was deter- 
mined by immunoblot (Fig. 8, A and B; Table If). Each get 
contained at least one and often two control samples for 
standardization.  Also,  with  the  exception  of  CG7  cells 
which  are  all  from  neonatal  adrenoleukodystrophy  pa- 
tients,  all  PBD  cells  chosen  for this  analysis  were  from 
Zellweger syndrome patients, reducing the possibility that 
partially defective alleles would skew the results. Relative 
to control fibroblasts, levels of Pex5p were reduced ~20- 
fold  in  each  of five different  CG1  ceils.  CG4 cells con- 
tained 7-20-fold less Pex5p, and the sole CG8 cell assayed 
contained only 1/7  the amount of Pex5p as control cells. 
Interestingly, CG1, 4, and 8 cells all share the ability to im- 
port  small  amounts  of  both  PTS1  and  PTS2  proteins 
(Slawecki et al., 1995), even in PEX6-deficient CG4 cells 
which  tack PEX6 mRNA  (Yahraus  et al.,  1996).  In con- 
trast to reduced Pex5p abundance in the group 1, 4, and 8 
Figure 7.  Pex5p is translocated into the peroxisome in CG7 cells. 
The distribution  of Pex5p was determined by indirect  immuno- 
fluorescence  using  our standard  protocol in  (A) normal fibro- 
blasts and (B) the CG7 cell line PBD054. (C) Differential (digito- 
nin)  permeabilization  of just  the  plasma membrane (digitonin 
permeabilization) rendered the peroxisome associated  Pex5p of 
PBD054  cells undetectable  in indirect  immunofluorescence  ex- 
periments.  Bar, 25 p~m. 
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Complementation  Patient  PexSp 
group  ID number  (Percent of normal) 
CG1  PBD002  4 
PBD009  7 
PBD022  3 
PBD045  5 
PBD047  6 
CG2  PBD005  0 
PB DO 18  90 
CG3  PBD006  162 
PBD040  140 
PBD098  162 
CG4  PBD010  13 
PBD051  5 
PBD011  14 
PBD039  4 
CG7  PBD052  106 
PBD053  157 
PBD054  112 
CG8  PBD059  14 
CG9  PBD061  144 
CG 10  PBD094  125 
PBD062  162 
CG 11  PBD073  95 
PBD082  113 
Figure 8.  The abundance of Pex5p is severely reduced in PBD 
cells from complementation groups 1, 4, and 8. (A) Immunoblot 
analysis  of Pex5p abundance in PBD and normal human fibro- 
blasts.  Equal amounts of total cellular protein from control and 
PBD  cell  lines  were  separated  by  SDS-PAGE, transferred  to 
membranes, and blotted with anti-Pex5p antibodies. Lane 1, the 
CG10 cell  line  PBD094; lane 2, the  normal fibroblast  line  N6 
(Slawecki  et al., 1995); lane 3, the CG1 cell line PBD002; lane 4, 
the CG4 cell line PBD010; lane 5, the CG4 cell line PBD039; lane 
6, the CG9 cell line PBD061; lane 7, the normal fibroblast line N7 
(Slawecki  et al.,  1995). (B) Levels of Pex5p in fibroblasts from 
PBD  patients  and  unaffected  controls  (Table  II) were  deter- 
mined by immunoblot of total cellular protein as shown above in 
A.  The  abundance  of Pex5p  was  plotted  by complementation 
group (CG) as the percent relative to control cell lines. Although 
Pex5p abundance was determined only once for most cell lines, 
multiple  independent  representatives  of most groups were  as- 
sayed. (C) The low abundance of Pex5p in CG1 fibroblasts is a 
function of receptor instability.  Control and CG1  (PBD002) fi- 
broblasts were pulse labeled with  [35S]methionine  and  [35S]cys- 
teine, washed, and either lysed immediately (0 h) or chased for 4, 
8, and 12 h. The t =  0 lysate was subjected to immunoprecipita- 
cells, levels of Pex5p were slightly elevated in the translo- 
cation deficient CG3 and CG10 cells and the Pex5p-import- 
ing CG7  cells.  CGll  cells,  which carry mutations  in  the 
PTS2  receptor  gene  PEX7,  contained  normal  levels  of 
Pex5p. Receptor levels were remarkably similar in differ- 
ent  cells  from  the  same  complementation  group  even 
though  only a  single  determination  of Pex5p  levels  was 
made for many of the cell lines studied. 
Levels of PEX5 mRNA were approximately equivalent 
in control and CG1, 4, and 8 cells (data not shown), indi- 
cating that the reduced levels of Pex5p in these PBD cells 
were not mediated by differential PEX5 mRNA synthesis 
or  stability.  Consistent  with  this  hypothesis,  pulse-chase 
experiments demonstrated that the half-life for Pex5p was 
,-~6 h in normal cells but reduced to less than 1 h in a CG1 
cell line (Fig. 8  C). The inability to calculate a  more pre- 
cise half life for Pex5p in CG1  cells was based on (1) the 
amount of Pex5p labeled at t =  0, (2) the fact that all of the 
Pex5p present at t =  0 was degraded by the 4-h time point, 
and  (3)  the  detection  limit  of the  assay.  Nevertheless,  a 
half-life less than  1 h  is in good agreement with the half- 
life of 20 min deduced from the immunoblot data and the 
6-h half-life of Pex5p in control cells. We did not perform 
the  necessary controls  that  would  allow  us  to make  any 
conclusions based on the relative amount of Pex5p labeled 
in control and  CG1  cells  during the  1-h pulse.  However, 
tion with both preimmune and immune sera; all other samples 
were precipitated with immune sera only. Quantitation of Pex5p 
abundance in each sample revealed that the half-life for Pex5p 
was 6 h in control cells and <1 h in CG1 cells. 
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sistent  with  a  half-life  of a  protein  that  is  significantly 
shorter than the duration of the pulse labeling period. The 
1-h half-life of Pex5p in CG4 cells (Yahraus et al., 1996), a 
sixfold reduction, is also consistent with the 7-20-fold re- 
duction in Pex5p levels in these cells. 
Discussion 
The PTS1 receptor has been identified in several different 
species, is required for import of PTS1 proteins into perox- 
isomes, and exhibits intrinsic PTSl-binding activity (Dodt 
et al., 1995; McCollum et al., 1993; van der Leij et al., 1993, 
1995).  Nevertheless, there are many aspects of PTS1 re- 
ceptor function that are in question. One of the most im- 
portant issues  is  whether the PTS1 receptor has a  static 
distribution, lying on the peroxisome surface, or has a dy- 
namic  distribution,  cycling  repeatedly  through  multiple 
cellular environments as  it transports  newly synthesized 
PTS1 proteins to the peroxisome. 
We have demonstrated that the PTS1 receptor in both 
human cells (Dodt et al., 1995) and the yeast P. pastoris 
(Gould et al.,  1996)  is a  predominantly cytoplasmic pro- 
tein, with ~5%  of the receptor found in association with 
the peroxisome under steady-state conditions. A  bimodal 
distribution for the receptor has also been observed by EI- 
gersma et al.  (1996) in the yeast S. cerevisiae and van der 
Klei et al.  (1995) in the yeast H. polymorpha.  However, 
several other reports on the yeast and human PTS1 recep- 
tor have suggested that this protein is exclusively associ- 
ated with the peroxisome membrane and may be an inte- 
gral peroxisomal membrane protein (Fransen et al., 1995; 
McCollum et al., 1993; Terlecky et al., 1995). Although we 
have no explanation for this alternative distribution of the 
mammalian  PTSI  receptor  reported  by  Fransen  et  al. 
(1995), the localization of the P. pastoris PTS1 receptor to 
just the peroxisome membrane by McCollum et al. (1993) 
and Terlecky et al.  (1995) was apparently due to experi- 
mental artifact (Gould et al., 1996).  Thus, the preponder- 
ance of evidence suggests that the PTS1 receptor is a pre- 
dominantly cytoplasmic protein. In the present report we 
have further defined the behavior of the PTS1 receptor by 
examining how its distribution and abundance is affected 
by  a  variety  of  genetic  and  environmental  conditions 
which inhibit protein import into the peroxisome. 
The observation that 95% of the PTS1 receptor is nor- 
mally present in the cytoplasm is, by itself, suggestive that 
that Pex5p functions as a cycling receptor. In this report 
we examined the possibility that defects in different steps 
of peroxisomal protein import might alter the distribution 
and/or abundance of the PTS1 receptor and whether such 
alterations might  confirm or refute the  cycling receptor 
hypothesis. Just  as blocking a  particular step in a  meta- 
bolic pathway leads to accumulation of the precursor for 
that step, blocking any step in the receptor's cycle should 
lead to accumulation of the receptor at the prior point in 
the  pathway.  Currently,  the  only aspect  of peroxisomal 
protein import that is generally accepted is that proteins 
are  translocated  across  the  peroxisome  membrane.  In 
the cycling receptor hypothesis, blocking the translocation 
step should result in accumulation of the PTS1 receptor 
at its docking site on the peroxisome surface, the step prior 
to translocation. Therefore, the relative amount of peroxi- 
some associated Pex5p should increase under these condi- 
tions. Our data demonstrate that the PTS1 receptor accu- 
mulates  on  or  near  the  surface  of  peroxisomes  when 
protein translocation is blocked, either by loss of putative 
protein translocation factors (PEX2 and PEX12) in PBD 
group 3 or 10 fibroblasts, or by low temperature incuba- 
tion and/or ATP depletion in normal fibroblasts. The fact 
that Pex5p is released from the peroxisome by reversing 
the translocation inhibiting conditions provides evidence 
that the receptor can return to the cytoplasm after accu- 
mulating on the peroxisome. The reaccumulation of Pex5p 
on peroxisomes by reapplication of the translocation in- 
hibiting conditions suggests that the receptor may be capa- 
ble of cycling repeatedly between the cytoplasm and the 
peroxisome. As expected, no accumulation of peroxisomal 
Pex5p was detected in PBD061 cells which lack detectable 
peroxisomal membranes (Chang, C.-C., G. Dodt, and S.J. 
Gould, manuscript in preparation). 
Blocking protein translocation into peroxisomes did not 
result in accumulation of all PTS1 receptors on the peroxi- 
some membrane. In the translocation defective CG10 cells 
that contained 5 times as much peroxisome associated re- 
ceptor peroxisomal Pex5p still represented just 25% of the 
total  receptor  molecules  in  the  cell.  This  may  well  be 
caused by greater abundance of PTS1 receptors relative to 
Pexl3p, the docking factor for the PTS1 receptor. Serial 
analysis  of gene expression (Velculescu et al.,  1995)  re- 
vealed that  human  cells contain four times  more  PEX5 
mRNA than PEX13 mRNA. If the relative abundance of 
Pex5p and Pex13p mirror the abundance of their respec- 
tive mRNAs, then the upper limit of Pex5p that could as- 
sociate with the peroxisome would be 25 %. The possibility 
that Pexl3p may limit peroxisomal accumulation of Pex5p 
is further supported by the observation that Pexl3p is  a 
low abundance protein of the peroxisome membrane (Erd- 
mann, R., personal communication; our unpublished ob- 
servations). 
The results of the translocation inhibition experiments 
support a model (Fig. 9) in which newly synthesized PTS1 
proteins are recognized in the cytoplasm by the PTS1 re- 
ceptor (step 1), with subsequent transport of the receptor- 
ligand  complex to the peroxisome (step 2),  followed by 
docking of the receptor-ligand complex to Pexl3p on the 
peroxisome surface  (step  3).  The surprising  observation 
that Pex5p was translocated into the peroxisome lumen in 
CG7 cells suggests two alternatives for the next step in im- 
port, either (4a) receptor-ligand dissociation at the trans- 
location pore, followed by ligand  translocation into  the 
peroxisome lumen and receptor recycling; or (4b) translo- 
cation of the receptor-ligand complex into the peroxisome 
lumen, followed by dissociation of the complex and export 
of the  receptor from the  peroxisome. The first of these 
models is consistent with a role for the CG7 gene product 
in dissociation of the receptor-ligand complex while the 
latter model would predict that the CG7 gene product is 
involved in exporting the PTS1 receptor from the peroxi- 
some lumen. Although we have no direct evidence for in- 
traperoxisomal  Pex5p  under  steady-state  conditions  in 
normal human fibroblasts, the PTS1 receptor in the yeast 
H. polymorpha (HpPex5p) has been detected in the lumen 
of the peroxisome in wild-type cells (van der Klei et al., 
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port is mediated by a cycling 
PTS1 receptor, The first step 
in import appears to involve 
recognition  of newly synthe- 
sized PTS1 proteins in the cy- 
toplasm by the PTS1 recep- 
tor. Next, the receptor-ligand 
complex is transported to the 
peroxisome.  This  process 
may involve one or more of 
the  peroxins  defective  in 
PBD  complementation 
groups  1,  4  (Pex6p),  and  8. 
Binding  of  this  complex to 
the  peroxisome  surface  ap- 
pears  to  be  limited,  consis- 
tent with  the  existence  of a 
saturable  docking  factor 
(Pexl3p; Gould et al., 1996). 
Protein  translocation  into 
peroxisomes  requires  the 
products  of  the  CG3 
(PEX12)  and CG10 (PEX2) 
genes and involves, at a mini- 
mum,  receptor-ligand  disso- 
ciation  with  subsequent 
ligand  translocation.  How- 
ever, translocation  of the re- 
ceptor  into  peroxisomes  in 
CG7 cell lines raises the pos- 
sibility  that  translocation 
normally occurs by import of 
the  receptor-ligand  complex 
with subsequent dissociation 
of the complex and receptor 
export.  After  delivering  its 
cargo  of  newly  synthesized 
PTS1 proteins to the peroxisome, the PTS1 receptor returns to the cytoplasm to repeat the cycle. The lack of detectable peroxisomes in 
CG9 cells suggests that synthesis of peroxisomal membranes and/or targeting of integral peroxisomal membrane proteins are distinct from 
matrix protein import. 
1995), providing direct support for the hypothesis that pro- 
tein import may normally involve movement of the PTS1 
receptor through the peroxisome lumen. 
The model for peroxisomal protein import that we have 
proposed is far from complete.  The  most obvious omis- 
sions are that it does not incorporate the import of PTS2 
proteins or IPMPs and does not explain the significance of 
the pre-import complex of newly synthesized peroxisomal 
proteins identified by Bellion and Goodman (1987).  Fur- 
thermore, certain details of the model have yet to be ob- 
served.  The  assumption  that  the  PTS1  receptor  binds 
newly synthesized proteins in the cytoplasm remains to be 
proven, the implication that Pex2p and Pex12p represent 
components  of  the  protein  translocation  pore  is  based 
solely on circumstantial evidence, and the implied role of 
the CG1, 4,  and 8 gene products in the early steps in the 
PTS1  receptor cycle are based primarily on the fact that 
the  phenotypes of these  cells are  so different from CG7 
cells which are defective in receptor recycling. Neverthe- 
less, this model integrates the data presented in this report 
with previous observations and should provide a focus for 
future studies of the import process. 
Peroxisomal  import  of an  intact  receptor-ligand com- 
plex, either as a normal step in import or as a consequence 
of a mutant translocation factor, would require formation 
of a  prohibitively large protein translocation pore.  How- 
ever, peroxisomal import of oligomeric protein complexes 
(Glover et  al.,  1994;  McNew  and  Goodman,  1994)  and 
large,  nondeformable  structures  such  as  PTS1  peptide- 
coated gold particles (Walton et al.,  1995)  have been ob- 
served. A  key question is whether such structures are ac- 
commodated  through  the  normal  translocation  pore  or 
whether  they  represent  an  artifactual  form  of  import. 
Identification of the gene defective in CG7 cells, the  na- 
ture  of the  inactivating  mutations  in  these  cells,  and  an 
analysis of the CG7 gene product should shed light on the 
mechanism  of protein  translocation  through  the  peroxi- 
some membrane. 
In  addition  to  the  altered  subcellular  distribution  of 
Pex5p in cell lines from PBD complementation groups 3, 
10, and 7, we observed that the steady-state abundance of 
Pex5p was severely reduced in CGs 1, 4,  and 8.  PEX5  is 
not  mutated  in  these  cell  lines  and  overexpression  of 
PEX5 cannot rescue their peroxisomal protein import de- 
fects  (Dodt  et  al.,  1995).  The  requirement  for  multiple 
gene products for Pex5p stability resembles the instability 
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phy patients who carry  mutations in the dystrophin gene 
or any  one  of the  a,  13, or ~/ sarcoglycan  genes  (Bonne- 
mann  et  al.,  1995;  Ervasti  et  al.,  1990;  Lira  et  al.,  1995; 
Noguchi et al., 1995). These proteins are all components of 
the  dystrophin-glycoprotein  complex,  a  high  molecular 
mass oligomeric complex. Based on this precedent, it may 
be that Pex5p physically interacts with the products of the 
CG1, CG4, and CG8 genes. Of these, only the CG4 gene 
(PEX6)  has been identified. PEX6 encodes a AAA  AT- 
Pase that is required for stability of the PTS1 receptor in 
yeast as well as in human cells (Yahraus et al., 1996; Reu- 
ber, B., and S.J. Gould, manuscript in preparation). Char- 
acterization of the CG1, 4, and 8 genes and gene products 
in cells from both normal and affected individuals will provide 
us with a better understanding of peroxisomal protein import. 
CG11  cells display a PTS2-specific import defect, carry 
inactivating  mutations  in the PTS2 receptor gene,  PEX7 
(Braverman,  N., S.J.  Gould, and D. Valle, manuscript in 
preparation), and import PTS1 proteins normally (Motley 
et al., 1994; Slawecki et al., 1995). We found no difference 
in the distribution or abundance of Pex5p in CGll cells as 
compared to normal fibroblasts. The fact that altered dis- 
tribution and/or abundance of Pex5p is restricted to those 
PBD  cell lines with a defect in import of PTS1  proteins, 
and is not observed in cells with a specific defect in PTS2 
protein  import  provides  further evidence  that  the  CG1, 
PEX12  (CG3),  PEX6  (CG4),  CG7,  CG8,  and  PEX2 
(CG10) gene products all play direct roles in peroxisomal 
matrix protein import. 
In  its  present  state,  our model of peroxisomal protein 
import resembles protein import into mitochondria (Ryan 
and Jensen, 1995), the nucleus (Powers and Forbes, 1994), 
and  the  endoplasmic  reticulum  (Walter  and  Lingappa, 
1986). All four import pathways use a predominantly cyto- 
plasmic targeting signal receptor that can cycle between the 
cytoplasm and organelle. The ubiquitous use of cytoplas- 
mic  receptors  for directing  newly synthesized  organellar 
proteins to their proper destination implies that diffusion 
alone cannot mediate  the transport of newly synthesized 
proteins from the cytoplasm to their appropriate target or- 
ganelle. However, if diffusion cannot mediate transport of 
proteins to target organelles, there is no reason to presume 
that diffusion alone could mediate transport of receptor- 
ligand complexes to the peroxisome. Therefore, it may be 
that multiple factors are involved in directing the PTS1 re- 
ceptor-ligand  complex from the cytoplasm to the peroxi- 
some.  It  will  be  particularly  interesting  to  determine 
whether the same gene products required for Pex5p stabil- 
ity are also involved in assembling this complex, directing 
it to the peroxisome or dissembling it once it docks to the 
peroxisome surface. 
We would like to thank A. Moser and H. Moser for the gift of PBD cell 
lines and J. Heyman and S. Subramani for the anti-PMP70 antibodies. 
This work was supported by a  grant from the National Institutes of 
Health (DK45787) to S.J. Gould. 
Received for publication 25 January 1996 and in revised form 23 Septem- 
ber 1996. 
References 
Baerends,  R.J.S., S.W. Rasmussen,  R.E~ Hilbrands,  M. van der Heide,  K.N. 
Faber, P.T.W. Reuvekamp, J.A.K.W. Kiel, J.M. Cregg, I.J. van der Klei, and 
M. Veenhuis. 1996. The Hansenula polymorpha PER9 gene encodes a per- 
oxisomal membrane protein  essential  for peroxisome  assembly and integ- 
rity. J. BioL Chem. 271:8887-8894. 
Bellion, E,, and J.M. Goodman.  1987. Proton ionophores prevent assembly of a 
peroxisomal protein. Cell. 48:165-173. 
Bonnemann,  C.G., R. Modi. S. Noguchi, Y. Mizuno, M. Yoshida, E. Gussoni, 
E.M. McNally, DJ. Duggan, C. Angelini, E.P. Hoffman, et al. 1995. !3-Sarcogly- 
can (A3b) mutations cause autosomal recessive muscular dystrophy with loss 
of the sarcoglycan complex. Nature Genet. 11:266--273. 
Cregg, J.M., l.J. Vankiel, G.J. SuRer, M. Veenhuis, and W. Harder.  1990. Per- 
oxisome-deficient mutants of Hansenula polymorpha.  Yeast.  6:87-97. 
de Hoop, M.J., and G.AB. 1992. Import of proteins into peroxisomes and other 
microbodies. Biochemistry. 286:657~669. 
Distel, B., R. Erdmann, S.J. Gould, G. Blobel, D.I. Crane, J.M. Cregg, G. Dodt, 
Y. Fujiki, J.M. Goodman, W.W. Just, et al. 1996. A unified nomenclature for 
peroxisome biogenesis. J. Cell Biol. 135:1-3. 
Dodt,  G., N. Braverman,  C. Wong, A.  Moser,  H.W. Moser,  P.  Watkins,  D. 
Valle, and S.J. Gould. 1995. Mutations in the PTS1 receptor gene, PXR1, de- 
fine complementation  group 2 of the peroxisome biogenesis disorders. Na- 
ture Genet. 9:115-124. 
Dyer, J.M., J.A. McNew, and J.M. Goodman, 1996. The sorting sequence of the 
peroxisomal integral membrane  protein  PMP47 is contained  within a short 
hydrophilic loop. Z Cell Biol. 133:269-280, 
Elgersma, Y., M. van den Berg, H.F. Tabak, and B. Distel. 1993. An efficient 
positive selection procedure for the isolation of peroxisomal import and per- 
oxisome assembly mutants of Saccharomyces cerevtsiae. Genetics.  135:731-740. 
Elgersma,  Y.,  L. Kwast, A.  Klein, T. Voorn-Brouwer,  M. van den  Berg, B. 
Metzig, T. America, H.F. Tabak, and B. Distel. 1996. The SH3 domain of the 
Saccharomyces cerevisiae peroxisomal membrane protein  Pexl3p  functions 
as a docking site for Pex5p, a mobile receptor  for the import of PTS1 con- 
taining proteins. J. Cell Biol. 135:97-109. 
Erdmann,  R.,  and  G. Blobel.  1996. Identification  of Pexl3p,  a peroxisomal 
membrane receptor  for the PTS1 recognition factor. J.  Cell Biol.  135:111- 
121. 
Erdmann,  R., D. Veenhuis,  D. Mertens, and W.H. Kunau.  1989. Isolation of 
peroxisome-deficient mutants of Saccharomyces cerevisiae.  Proc. Natl. Acad. 
Sci.  USA. 86:5419-5423. 
Ervasti, J.M., K. Ohlendieck, S.D. Kahl, M.G. Gaver, and K.P. Campbell. 1990. 
Deficiency of a glycoprotein component  of the dystrophin complex in dys- 
trophic muscle. Nature (Lond.). 345:315-319. 
Fransen,  M., C. Brees, E. Baumgart,  J.C.T. Vanhooren,  M, Baes, G.P. Man- 
naerts, and P.P. van Veldhoven. 1995. Identification and characterization  of 
the putative  human peroxisomal C-terminal targeting signal import recep- 
tor. J. Biol. Chem. 270:7731-7736. 
Glover, J.R., D.W. Andrews, and R.A. Rachubinski. 1994. Saccharomyces cere- 
visiae peroxisomal  thiolase  is imported  as a dimer.  Proc.  Natl.  Acad.  Sci. 
USA. 91:10541-10545. 
Gould,  SJ., J.E.  Kalish, J.C. Morrell, J.  Bjorkman,  A.J.  Urquhart,  and  D.I. 
Crane. 1996. Pex13p is an SH3 protein  of the peroxisome membrane and a 
docking  factor  for the  predominantly  cytoplasmic PTS1 receptor.  J.  Cell 
Biol. 135:85-95. 
Gould, S.J., G,A. Keller, N. Hosken, J. Wilkinson, and S. Subramani. 1989. A 
conserved tripeptide  sorts proteins  to peroxisomes. J.  Cell Biol.  108:1657- 
1664. 
Gould, S.J., D. McCollum, A.P. Spong, J.A. Heyman, and S. Subramani. 1992. 
Development  of the yeast Pichia pastoris as a model organism for a genetic 
and molecular analysis of peroxisome assembly. Yeast.  8:613-628. 
Heyman, J.A., E. Mononsov, and S. Subramani. 1994. Role of the PAS1 gene of 
Pichia pastoris in peroxisome biogenesis. J. Cell Biol. 127:1259-1273. 
Imanaka, T., G.M. Small, and P.B. Lazarow. 1987. Translocation  of acyl-CoA 
oxidase into peroxisomes requires ATP hydrolysis but not a membrane po- 
tential. Z Cell Biol. 105:2915-2922. 
Kalish, J.E., C. Theda, J.C. Morrell, J.M. Berg, and S.J. Gould. 1995. Formation 
of the peroxisome lumen is abolished by loss of Pichia pastoris PasTp, a zinc- 
binding integral  membrane  protein  of the peroxisome. Mot.  Cell.  Biol.  15: 
6406-6419. 
Kalish, J.E., G.A. Keller, J.C. Morrell, S.J. Mihalik, B. Smith, J.M. Cregg, and 
S.J. Gould. 1996. Characterization  of a novel component of the peroxisomal 
protein  import  apparatus  using fluorescent  peroxisomal  proteins.  EMBO 
(Eur. Mol. Biol. Organ.) J. 15:3275-3285. 
Kragler, F., A. Langeder, J. Raupachova, M. Binder, and A. Hartig. 1993. Two 
independent  peroxisomal targeting signals in catalase A of Saccharomyces 
cerevisiae.  J. Cell Biol. 120:665--673. 
Lazarow, P.B., and H.W. Moser. 1995. Disorders of peroxisome biogenesis. In 
The Metabolic  and  Molecular  Bases of Inherited  Disease.  C.  Scriver, A. 
Beaudet, W. Sly, and D. Valle, editors. McGraw-Hill, New York. 2287-2324. 
Lim, L.E., F. Duclos, O. Broux, N. Bourg, Y. Sunada, V. Allamand, J. Meyer, I. 
Richard, C. Moomaw, C. Slaughter, et al. 1995.13-Sarcoglycan: characteriza- 
tion  and  role  in  limb-girdle  muscular  dystrophy  linked  to  4q12. Nature 
Genet. 11:257-265. 
Liu, H., X. Tan, M. Veenhuis, D. McCollum, and J.M. Cregg. 1992. An efficient 
screen for peroxisome-deficient mutants of Pichia pastoris. Z  Bacteriol.  174: 
4943-4951. 
Luers, G., T. Hashimoto, H.D. Fahimi, and A. Volkl. 1993. Biogenesis of perox- 
Dodt and Gould A  Cycling Receptor  for PTS1 Proteins  1773 isomes: isolation and characterization  of two distinct peroxisomal popula- 
tions from normal and regenerating rat liver. J. Cell Biol. 121:1271-1280. 
Marzioch, M., R. Erdmann,  M. Veenhuis,  and W.H. Kunau,  1994. PAS7 en- 
codes a novel yeast member of the WD-40 protein  family essential for im- 
port  of 3-oxoacyl-CoA  thiolase,  a  PTS2-containing protein,  into  peroxi- 
somes. EMBO (Eur. Mol. Biol. Organ.) J. 13:4908-4918. 
McCollum, D., E. Monosov, and S. Subramani. 1993. The pas8 mutant of Pichia 
pastoris exhibits the  peroxisomal protein  import  deficiencies of Zellweger 
syndrome cells. The PAS8 protein  binds to the COOH-terminal  tripeptide 
peroxisomal targeting signal and is a member of the TPR protein family. J. 
Cell Biol. 121:761-774. 
McNew, J.A., and J.M. Goodman. 1994. An oligomeric protein is imported into 
peroxisomes in vivo. J. Cell Biol. 127:1245-1257. 
Miyazawa, S., T. Osumi, T. Hashimoto, K. Obno, S. Miura, and Y. Fujiki. 1989. 
Peroxisomal targeting signal of rat liver acyl-coenzyme A oxidase residues at 
the carboxy terminus. Mol. Cell. BioL 9:83-91. 
Moser, A.B., M. Rasmussen, S. Naidu, P. Watkins, M. McGuinnes, A.K. Hajra, 
G. Chen, G. Raymond, A. Liu, D. Gordon, et al. 1995. Phenotype of 139 per- 
oxisome disorder  patients  subdivided into  13  complementation  groups. J. 
Pediatr.  127:13-22. 
Motley, A., E. Hettema, B. Distel, and H. Tabak. 1994. Differential protein im- 
port deficiencies in human peroxisome assembly disorders. J. Cell BioL 125: 
755-767. 
Noguchi,  S.,  E.M. McNally,  K.B. Othmane,  Y.  Hagiwara,  Y.  Mizuno,  M. 
Yoshida, H. Yamamoto, C.G. Bonnemann, E. Gussoni, P.H. Denton,  et al. 
1995. Mutations in the dystrophin-associated protein 3,-sarcoglycan in chro- 
mosome 13 muscular dystrophy. Science (Wash. DC). 270:819-822. 
Nuttley,  W.M., A.M. Brade,  C.  Gaillardin,  G.A.  Eitzen,  J.R.  Glover,  J.D. 
Aitchinson, and R.A. Rachubinski. 1993. Rapid identification and character- 
ization of peroxisomal  assembly mutants  in  Yarrowia lipolytica.  Yeast.  9: 
507-517. 
Osumi, T., T. Tsukamoto, S. Hata, S. Yokota, S. Miura, Y. Fujiki, M. Hijikata, 
S. Miyazawa, and T. Hashimoto.  1991. Amino-terminal  presequence  of the 
precursor of peroxisomal 3-ketoacyl-CoA thiolase is a cleavable signal pep- 
tide for peroxisomal targeting. Biochem. Biophys. Res. Comm. 181:947-954. 
Powers, M.A., and  D3. Forbes.  1994. Cytosolic factors in nuclear  transport: 
what's importin? Cell. 79:931-934. 
Ryan, K.R., and R.E. Jensen. 1995. Protein translocation across mitochondrial 
membranes: what a long strange trip it is. Cell, 83:517-519. 
Santos, M., T. Imanaka, H. Shio, G.M. Small, and P.B. Lazarow. 1988. Peroxi- 
somal membrane  ghosts in Zellweger syndrome- aberrant  organelle assem- 
bly. Science (Wash. DC). 239:1536-1538. 
Shimozawa, N., T. Tsukamoto, Y. Suzuki, T. Orii, Y. Shirayoshi, T. Mori, and 
Y. Fujiki. 1992. A human gene responsible for Zellweger syndrome that af- 
fects peroxisome assembly. Science (Wash. DC). 255:1132-1134. 
Shimozawa, N., Y. Suzuki, T. Orii, A. Moser, H.W. Moser, and R.J.A. Wan- 
ders.  1993. Standardization  of complementation  grouping  of peroxisome- 
deficient disorders  and the second Zellweger patient  with peroxisomal as- 
sembly factor-I (PAF-I) defect. Am. J. Hum. Genet. 52:843-844. 
Slawecki, M., G. Dodt, S. Steinberg, A.B. Moser, H.W. Moser, and S.J. Gould. 
1995. Identification  of three  distinct peroxisomal protein  import defects in 
patients with peroxisomal biogenesis disorders. J. Cell Sci. 108:1817-1829. 
Small, G., L. Szabo, and P. Lazarow. 1988. Acyl-CoA oxidase contains two tar- 
geting sequences  each  of which can  mediate  protein  import  into  peroxi- 
somes. EMBO (Eur. MoL Biol. Organ.) J. 7:1167-1173. 
Spong, A.P., and S. Subramani. 1993. Cloning and characterization  of PAS5: a 
gene required for peroxisome biogenesis in the methylotrophic yeast Pichia 
pastoris.  J. Cell Biol. 123:535-548. 
Subramani, S. 1993. Protein import into peroxisomes and biogenesis of the or- 
ganelle. Annu. Rev. Cell BioL 9:445478. 
Swinkels, B.W., S.J. Gould, A.G. Bodnar, R.A. Rachubinski, and S. Subramani. 
1991. A novel, cleavable peroxisomal targeting signal at the amino-terminus 
of the rat 3-ketoacyl-CoA thiolase. EMBO (Eur.  MoL  Biol.  Organ.) J.  10: 
3255-3262. 
Terlecky, S.R., W.M. Nuttley, D. McCollum, E. Sock, and S. Subramani. 1995. 
The Pichia pastoris peroxisomal protein Pas8p is the receptor for the C-ter- 
minal tripeptide  peroxisomal targeting signal. EMBO (Eur  Mol.  BioL Or- 
gan.) J. 14:3627-3634. 
van der Leij, I,, M.M. Franse, Y. Elgersma, B. Distel, and H.F. Tabak.  1993. 
PAS10 is a tetratricopeptide-repeat  protein that is essential for the import of 
most matrix proteins  into peroxisomes  of Saccharomyces cerevisiae.  Proc. 
Natl. Acad. Sci . USA. 90:11782-11786. 
van der Klei, I.J., R.E. Hibrands, G.J. Swaving, H.R. Waterham, E.G. Vrieling, 
V.1. Titorenko,  J.M. Cregg,  W.  Harder,  and  M.  Veenhuis.  1995. The 
Hansenula polymorpha PER3 gene is essential for the import of PTS1 pro- 
teins into the peroxisome matrix. J. Biol. Chem. 270:17229-17236 
Velculescu, V.E., L. Zhang, B. Vogelstein, and K.W. Kinzler. 1995. Serial anal- 
ysis of gene expression. Science (Wash. DC). 270:484-487. 
Walter, P., and V.R. Lingappa. 1986. Mechanism of protein translocation across 
the endoplasmic reticulum membrane. Annu. Rev. Cell Biol. 2:499-516. 
Walton, P.A., S.J. Gould, J.R. Feramisco, and S. Subramani, 1992. Transport of 
microinjected  proteins  into  peroxisomes  of mammalian  cells: inability of 
Zellweger cell lines to import proteins with the SKL tripeptide  peroxisomal 
targeting signal. Mol. Cell Biol. 12:531-541. 
Walton, P.A., P. Hill, and S. Subramani. 1995. Import of stably folded proteins 
into peroxisomes. Mol. Biol. Cell. 6:675-683. 
Waterham,  H.R., V.I. Titorenko,  G.J. Swaving, W. Harder,  and M. Veenhis. 
1993. Peroxisomes in the methyltrophic yeast Hansenula polymorpha do not 
necessarily derive from pre-existing organelles. EMBO (Eur. Mol, Biol. Or- 
gan.) Z 12:4785~,794. 
Wendland, M., and S. Subramani.  1993. Cytosol-dependent  peroxisomal pro- 
tein import in a permeabilized cell system. J. Cell Biol. 120:675-685. 
Wiemer, E.A.C., W.M. Nuttley, B.L. Bertolaet,  X. Li, U. Franke, M.J. Whee- 
lock, W.K. Anne, K.R. Johnson, and S. Subramani. 1995. Human peroxiso- 
mal targeting signal-1 receptor  restores peroxisomal protein  import in cells 
from patients with fatal peroxisomal disorders. J. Cell BioL 130:51-65, 
Wiemer, E.A.C., G.H. Liiers, K.N. Faber, T. Wenzel, M. Veenhuis, and S. Sub- 
ramani. 1996. Isolation and characterization  of Pas2p, a peroxisomal mem- 
brane  protein  essential  for peroxisome  biogenesis  in  the  methylotrophic 
yeast Pichia pastoris. J. Biol. Chem. 271:18973-18980. 
Yahraus, T., N. Braverman, G. Dodt, J.E. Kalish, J.C. Morrell, H.W. Moser, D. 
Valle, and S.J. Gould.  1996. The peroxisome  biogenesis disorder  group 4 
gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the 
PTSI receptor. EMBO (Eur. MoL Biol. Organ.) J. 15:2914-2923. 
Zhang, J.W., and P.B. Lazarow. 1995. PEB1 (PAS7) in Saccharomyces cerevi- 
siae encodes a hydrophilic, intra-peroxisomal protein that is a member of the 
WD repeat family and is essential for the  import  of thiolase  into peroxi- 
somes. Z Cell Biol, 129:65-80. 
The Journal of Cell Biology, Volume 135, 1996  1774 